IBRX | NASDAQ
$8.83
$0.31 | 3.64%
SIGNAL:
|2026-09-25
|F&G 62
|RSI 56.7
|2026-09-25
|F&G 62
|RSI 56.7
Company Overview:
Market Cap:
$9.36B
Trailing PE:
N/A
FWD PE:
—
Payout Ratio (TTM):
—
52-Week Range:
$1.95 - $12.43
10 Year IBRX Performance Metrics:
Total Return (with DRIP):
13.5% (1.27% CAGR)
Total Return (no DRIP):
13.5% (1.27% CAGR)
Share Price:
13.5% (1.27% CAGR)
Yield on Cost (with DRIP):
—
Total Invested:
$10,000
Total Value (with DRIP):
$11,350
Total Return $ (with DRIP):
$1,350
IBRX Total Return
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
IBRX Price Chart
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
All
Unlock All Reports & Research Dividend Stocks like a BOSS!
Save 25% with annual plan (3 Months Free)
Save 25% with annual plan (3 Months Free)
Pro
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Stock Fundamentals
- DCF valuation modeling
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
You save $7.60 (40%)
Most Popular
Premium
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- Stocks Dashboard
You save $12.80 (40%)
Ultra
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $25.60 (40%)
Pro
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Stock Fundamentals
- DCF valuation modeling
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
You save $125.40 (55%)
Most Popular
Premium
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- Stocks Dashboard
You save $211.20 (55%)
Ultra
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $422.40 (55%)
IBRX Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
IBRX Revenue CAGR:1Y: 93.91%2Y: 599.57%5Y: 172.82%10Y: 130.70%
IBRX EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
IBRX EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Gross Profit CAGR:1Y: 93.78%2Y: 597.53%5Y: 172.51%10Y: 130.56%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Shares Outstanding CAGR:1Y: 18.22%2Y: 23.64%5Y: 22.23%10Y: 12.35%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.77%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Stock-Based Comp CAGR:1Y: 72.96%2Y: 31.57%5Y: -1.35%10Y: -3.32%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Expenses CAGR:1Y: 389.55%2Y: 170.36%5Y: -8.04%10Y: 17.49%
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
IBRX Revenue CAGR:1Y: 93.91%2Y: 599.57%5Y: 172.82%10Y: 130.70%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Revenue CAGR:1Y: 93.91%2Y: 599.57%5Y: 172.82%10Y: 130.70%
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
🔓 See the full chart40% off right now · 7-day free trial
IBRX Actual Revenue CAGR:1Y: 93.91%2Y: 599.57%5Y: 172.82%10Y: 130.70%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Ratios, Profit Margins & Return on Capital:
🔓 See the full chart40% off right now · 7-day free trial
IBRX Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Gross Profit Margin CAGR:1Y: -0.07%2Y: -0.29%5Y: -0.12%10Y: -0.06%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Price To Sales Ratio CAGR:1Y: 102.30%2Y: -79.11%5Y: -59.37%10Y: -49.61%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
IBRX Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Projected Future Returns & Dividends for IBRX
Based on past 10-year performance, here are IBRX growth metrics:
Share price CAGR of +1.78%
Dividend CAGR of +0%
Using IBRX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| IBRX (DRIP) | IBRX - No DRIP | |
|---|---|---|
| Current Price | $8.83 | $8.83 |
| Start Shares | 1,132.50 | 1,132.50 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 1,132.50 | 1,132.50 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $8.83 | $8.83 |
| Total Dividends | $0 | $0 |
| Final Value | $10,000 | $10,000 |
Estimated Future Value + Dividends - IBRX
NOTE: Above numbers are our estimate based on IBRX's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Save 25% with annual plan (3 Months Free)
Save 25% with annual plan (3 Months Free)
Pro
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Stock Fundamentals
- DCF valuation modeling
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
You save $7.60 (40%)
Most Popular
Premium
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- Stocks Dashboard
You save $12.80 (40%)
Ultra
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $25.60 (40%)
Pro
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Stock Fundamentals
- DCF valuation modeling
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
You save $125.40 (55%)
Most Popular
Premium
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- Stocks Dashboard
You save $211.20 (55%)
Ultra
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $422.40 (55%)
Company Info
ImmunityBio, Inc. (IBRX) had its IPO on 2015-07-28, and is traded on NASDAQ stock exchange.
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
IBRX website: https://immunitybio.com
Get Full Access to All Reports with DRIPCalc PRO
Save 25% with annual plan (3 Months Free)
Save 25% with annual plan (3 Months Free)
Pro
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Stock Fundamentals
- DCF valuation modeling
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
You save $7.60 (40%)
Most Popular
Premium
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- Stocks Dashboard
You save $12.80 (40%)
Ultra
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $25.60 (40%)
Pro
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Stock Fundamentals
- DCF valuation modeling
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
You save $125.40 (55%)
Most Popular
Premium
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- Stocks Dashboard
You save $211.20 (55%)
Ultra
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $422.40 (55%)
Loading signals…
DCF Model — IBRX
Value from:
🔒 Upgrade to unlock
The full DCF valuation — fair value, implied growth and the price path — is a paid feature.
Upgrade
Pay up to today
—
vs current price $8.83
—
Cash flow & implied price by year
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
| Year | FCF | Implied price |
|---|
Sensitivity — fair value: growth ↓ × target return →
